1. Longevity Health Holdings announces merger with True Health Inc. (THPlasma). 2. After merger, combined company trades as XAGE on Nasdaq. 3. THPlasma aims to expand from 2 to 5 centers and enhance profitability. 4. The merger supports overcoming U.S. plasma shortfall. 5. Longevity's recent mergers may enhance customer value proposition.

1. Aptorum Group merges with DiamiR Biosciences in an all-stock deal. 2. DiamiR becomes a wholly-owned subsidiary and focuses on brain health. 3. Shareholders will vote on the merger and potential reverse stock split. 4. The combined company aims to lead in biopharma services and blood-based diagnostics. 5. Merger expected to close in Q4 2025, enhancing revenue generation potential.

1. Monogram to be acquired by Zimmer Biomet for $4.04 per share. 2. Stockholders may receive up to $12.37 per share based on milestones. 3. Transaction expected to drive revenue growth by 2027 and beyond. 4. Zimmer Biomet aims to lead in fully autonomous orthopedic robotics. 5. Closure pending regulatory approvals and stockholder consent.

1. Sonnet is combining with Rorschach to create Hyperliquid Strategies Inc. 2. The new entity will manage $888 million in value including 12.6 million HYPE tokens. 3. Sonnet aims to leverage this partnership to enhance biotech asset funding. 4. The merger is subject to approval from Sonnet's stockholders and final closing conditions. 5. Sonnet will continue to focus on its biotech assets and develop SON-1010.

1. Pagaya expects Q2 2025 results to exceed prior guidance. 2. Focus on optimizing balance sheet to reduce capital costs. 3. No plans to issue equity or linked instruments soon. 4. Strong execution noted in financial performance for growth. 5. Final Q2 results will be reported on August 7, 2025.